Semax is a synthetic heptapeptide nootropic derived from a fragment of adrenocorticotropic hormone (ACTH 4-10). Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s, it is one of Russia's most well-studied nootropics and is approved there as a prescription medication for stroke recovery, cognitive disorders, optic nerve disease, and peptic ulcers. Semax modulates BDNF, serotonin, dopamine, and the immune system. It is administered intranasally due to its peptide nature and has a remarkably favorable safety profile with decades of clinical use in Russia.
Harm Reduction
Semax is administered intranasally, typically as a 0.1% solution delivering approximately 50-100 mcg per spray. Standard dosing is 200-600 mcg (2-6 sprays) per day, divided into 2-3 administrations. H...
Read full harm reduction guide